VivoSeq
Other

Tenofovir Disoproxil Fumarate

0

Pipeline Programs↗

4

Active Trials↗

12

Companies Involved↗

Tenofovir Disoproxil Fumarate is an early-stage landscape with 0 programs across 12 companies. The most active players are Gilead, Johnson & Johnson, GSK.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalIlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd

0 programs

PreclinicalA

Alios Biopharma Inc.

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

55

clinical trials

Completed43 · 78%
Unknown status5 · 9%
Terminated3 · 5%
Active, not recruiting2 · 4%
Recruiting1 · 2%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

55 trials

Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 1·NCT06356662·60 enrolled
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Active, not recruiting·Gilead logoGilead·Phase 2·NCT06101329·253 enrolled
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Active, not recruiting·Gilead logoGilead·Phase 2·NCT06101342·181 enrolled
Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide
Not yet recruiting·BBeijing Continent Pharmaceutical Co, Ltd.·Phase 1·NCT07295873·64 enrolled
Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs
Completed·Gilead logoGilead·N/A·NCT00016588
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Completed·Gilead logoGilead·Phase 3·NCT01309243·799 enrolled
Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects
Completed·GSK logoGSK·Phase 1·NCT01480622·14 enrolled
Tenofovir Disoproxil Fumarate to Treat Pediatric HIV
Completed·National Cancer Institute (NCI)·Phase 1·NCT00024986·30 enrolled
A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT02431247·725 enrolled
Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00660972·40 enrolled
Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study
Completed·HHospital Clinic of Barcelona·Phase 4·NCT04233372·399 enrolled
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring
Completed·—·Phase 1·NCT02006264·30 enrolled
Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine
Completed·Gilead logoGilead·Phase 3·NCT00737568·280 enrolled
Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03593655·247 enrolled
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Completed·CCONRAD·Phase 2·NCT01687218·195 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)